LungBlog

People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the Department of Epidemiology at The University of Texas M. D. Anderson Cancer Center.”About 15 percent of lung cancers occur in lifetime never smokers. Risk factors for lung cancer in people who have never smoked are poorly understood, but this study demonstrates that poor DNA repair capacity is an important predictor of lung cancer risk in never smokers,” said the study’s lead author, Olga Gorlova, Ph.D., an assistant professor in the Department of Epidemiology.

MedPredict has published a new report in its oncology series entitled “Thought Leader Insight & Analysis: Lung Cancer,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in non-small cell and small cell lung cancer.

Peruvian doctors are to perform clinical tests to verify the efficacy of the therapeutic vaccine launched in Cuba to prolong a lung cancer patients’ life, said today the director of Peru’s National Institute of Neoplastic Diseases (INEN), Carlos Vallejos.

People living in Livonia and Fordoche say they’re noticing a lot of their neighbors are being diagnosed with cancer. Now, they want to know if they are at risk. One Livonia woman is even keeping a list of neighbors who have died from cancer.

Today, Lung Cancer Alliance (LCA) hailed the introduction of legislation that creates the first ever multi-agency, comprehensive program targeted at lung cancer and authorizes $75 million to start the first phase of the five year program to reduce lung cancer mortality.

As part of its mission the CIP takes the lead in planning and recruiting for a number of imaging-related clinical trials, as summarized on the Web site at: http://imaging. cancer.gov/ clinicaltiials/. These include screening and interventional trials, trials assessing imaging response criteria, single-institution feasibility trials (R21), phase 1 and 2 trials, and ACRIN trials. Current phase 3 ACRIN trials all involve PET, including PET to: monitor treatment for malignant gastrointestinal stromal tumors, predict treatment response in lung cancer, and evaluate treatment response in lung cancer.

A number of oncology-specific PET indications for ^sup 18^F-FDG have been approved or partially approved by CMS. These include applications in solitary pulmonary nodules (SPNs), non-small cell lung cancer, colon cancer, Hodgkin’s and non-Hodgkin’s lymphomas (NHL), melanoma, head and neck cancer, esophageal cancer, thyroid cancer, and breast cancer.

The new BSD-2000 in Liaocheng delivers precision-focused RF energy into cancerous tumors, including those located deep in the body, raising the tumor temperature to levels used to administer hyperthermia therapy and destroy cancer cells with heat along with increasing the effectiveness of radiation therapy. Liaocheng Peoples Hospital plans to treat cervical cancer and other pelvic cancers as well as research the treatment of lung cancer with the new BSD-2000 system. Lung cancer cases continue to increase in many parts of the world, and it is the most prevalent cancer in China.

The home of the cigar, Cuba, has approved what’s billed as the world’s first lung cancer vaccine. It’s now available in the island’s hospitals.

Cuban doctors say it increases patient survival rates. But Australian specialists say they need to see more information about the testing the vaccine went through.

The biggest cancer killer in Liverpool is lung cancer, accounting for 400 – or just under a third – of deaths every year.

Joan Elmer, a project worker at the Liverpool Cancer Support Centre, in Aigburth, said: “There has been a sharp rise, but you have to remember that survival rates have also increased.

“Early detection is vital. It gives you a much better chance of survival. People should always consider that if in doubt, they should seek help instantly.”